Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Letters to the Editor

Reduction of Myeloperoxidase Activity by Melatonin and Pycnogenol May Contribute to their Blood Pressure Lowering Effect

Leonard P. van der Zwan, Peter G. Scheffer, Tom Teerlink
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.110.158170
Hypertension. 2010;56:e34
Originally published August 18, 2010
Leonard P. van der Zwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter G. Scheffer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Teerlink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • eLetters
Loading

To the Editor:

In a recent issue of Hypertension, Rezzani et al reported that 6 weeks of treatment with either melatonin or pycnogenol, a pine bark extract rich in flavonoids, protected structure and function of the microvasculature in spontaneously hypertensive rats and resulted in a reduction in systolic blood pressure.1 These effects were ascribed to the antioxidant properties of both compounds that reduce oxidative stress and increase the availability of nitric oxide by several mechanisms as depicted in the figure in the accompanying editorial.2 We would like to propose reduction of the activity of the oxidative enzyme myeloperoxidase (MPO) as an additional mechanism.

MPO, an enzyme linked to both inflammation and oxidative stress, catalyzes the production of hypochlorous acid and a range of other highly reactive species, which, by killing pathogens, play a protective role in the innate immune response. In the vasculature, however, these MPO-derived reactive substances may lead to structural damage and reduce the bioavailability of the endogenous vasodilator nitric oxide. Accordingly, MPO is associated with the initiation and propagation of cardiovascular disease.3 We recently observed a positive association between levels of MPO and both systolic and diastolic blood pressure in a population-based cohort of elderly subjects.4 Because hydrogen peroxide is an obligate cosubstrate of MPO, the activity of MPO in the vasculature is enhanced by increased local production of reactive oxygen species. In other words, MPO has the ability to amplify oxidative stress, by using hydrogen peroxide to form reactive oxidant species with a higher oxidative potential. In accordance with this notion, the relationship between MPO and blood pressure was strongest in individuals with features associated with increased oxidative stress, such as obesity, low levels of high-density lipoprotein cholesterol, the metabolic syndrome, and type 2 diabetes.4

Interestingly, Galijasevic et al identified melatonin as a potent inhibitor of MPO.5 They showed that, at physiological and supplemental concentrations, melatonin interferes with the catalytic activity of MPO by multiple pathways, including switching the activity of MPO from peroxidation to catalase-like activity and conversion of MPO to an inactive form.

Next to inhibition of MPO, melatonin may also reduce the activity of MPO in the vasculature by 2 other mechanisms that may also apply to pycnogenol. First, both compounds are potent scavengers of reactive oxygen species and may thereby limit the production of hydrogen peroxide, the cosubstrate of MPO. Second, the antiinflammatory properties of melatonin and pycnogenol may reduce infiltration of the vascular wall by MPO-secreting leukocytes.

In summary, we propose that, in addition to the mechanisms suggested by Rezzani et al, a reduction of vascular MPO activity likely contributes to the vasoprotective and blood pressure–lowering effects of melatonin and pycnogenol.

Acknowledgments

Disclosures

None.

References

  1. ↵
    Rezzani R, Porteri E, De Ciuceis C, Bonomini F, Rodella LF, Paiardi S, Boari GEM, Platto C, Pilu A, Avanzi D, Rizzoni D, Agabiti Rosei E. Effects of melatonin and pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension. 2010; 55: 1373–1380.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Ferri C, Grassi D. Antioxidants and beneficial microvascular effects: is this the remedy? Hypertension. 2010; 55: 1310–1311.
    OpenUrlFREE Full Text
  3. ↵
    Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009; 55: 1462–1470.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension. 2010; 55: 1366–1372.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Galijasevic S, Abdulhamid I, Abu-Soud HM. Melatonin is a potent inhibitor for myeloperoxidase. Biochemistry. 2008; 47: 2668–2677.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
September 2010, Volume 56, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Reduction of Myeloperoxidase Activity by Melatonin and Pycnogenol May Contribute to their Blood Pressure Lowering Effect
    Leonard P. van der Zwan, Peter G. Scheffer and Tom Teerlink
    Hypertension. 2010;56:e34, originally published August 18, 2010
    https://doi.org/10.1161/HYPERTENSIONAHA.110.158170

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Reduction of Myeloperoxidase Activity by Melatonin and Pycnogenol May Contribute to their Blood Pressure Lowering Effect
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Reduction of Myeloperoxidase Activity by Melatonin and Pycnogenol May Contribute to their Blood Pressure Lowering Effect
    Leonard P. van der Zwan, Peter G. Scheffer and Tom Teerlink
    Hypertension. 2010;56:e34, originally published August 18, 2010
    https://doi.org/10.1161/HYPERTENSIONAHA.110.158170
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Epidemiology, Lifestyle, and Prevention
    • Epidemiology
  • Basic, Translational, and Clinical Research
    • Animal Models of Human Disease

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured